Decoy Therapeutics is trading at $2.19, down 5.41%, with no clear catalyst established.

  • September 29 preclinical data showed a single intranasal dose maintained therapeutic drug levels in nasal and lung tissue for up to seven days.
  • Clinical trials are expected in 2027.
  • The announcement did not report a share-price reaction or link the findings to the decline. Major indexes were lower, but none was down more than 0.5%.